Literature DB >> 1924719

Quinolone therapy in the prevention of mortality after irradiation.

I Brook1, T B Elliott.   

Abstract

The effect of oral therapy with three quinolones (ofloxacin, ciprofloxacin, and pefloxacin) in the prevention of postirradiation bacteremia and mortality was tested in B6D2F1 mice given 9.5 Gy 60Co gamma radiation. Only 8 of 60 (13%) untreated mice survived for 30 days, compared to 47 of 60 (78%) mice treated with ofloxacin, 44 of 60 (74%) mice treated with ciprofloxacin, and 42 of 60 (70%) mice treated with pefloxacin (P less than 0.05). The organisms recovered from the mice were Streptococcus spp. and Enterobacteriaceae. More Enterobacteriaceae were recovered from the livers of untreated animals than from the mice treated with the quinolones. However, no reduction in the number of Streptococcus spp. was noted in the animals given quinolones when compared to controls. This study shows that quinolones prolonged survival and decreased systemic spread of Enterobacteriaceae up to 30 days after exposure of mice to lethal irradiation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1924719

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  9 in total

1.  Antibiotic administration in the drinking water of mice.

Authors:  James O Marx; Daljit Vudathala; Lisa Murphy; Shelley Rankin; F Claire Hankenson
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-05       Impact factor: 1.232

2.  Antimicrobial therapy for bacillus anthracis-induced polymicrobial infection in (60)Co gamma-irradiated mice.

Authors:  Thomas B Elliott; Itzhak Brook; Rita A Harding; S Samy Bouhaouala; Michael O Shoemaker; Gregory B Knudson
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

3.  Evaluation of hydration and nutritional gels as supportive care after total-body irradiation in mice (Mus musculus).

Authors:  Krinon D Moccia; Cara H Olsen; Jennifer M Mitchell; Michael R Landauer
Journal:  J Am Assoc Lab Anim Sci       Date:  2010-05       Impact factor: 1.232

4.  Adverse effects of pefloxacin in irradiated C3H/HeN mice: correction with glucan therapy.

Authors:  M L Patchen; I Brook; T B Elliott; W E Jackson
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

5.  High-throughput screening identifies two classes of antibiotics as radioprotectors: tetracyclines and fluoroquinolones.

Authors:  Kwanghee Kim; Julianne M Pollard; Andrew J Norris; J Tyson McDonald; Yingli Sun; Ewa Micewicz; Kelly Pettijohn; Robert Damoiseaux; Keisuke S Iwamoto; James W Sayre; Brendan D Price; Richard A Gatti; William H McBride
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531

6.  Establishing a murine model of the hematopoietic syndrome of the acute radiation syndrome.

Authors:  P Artur Plett; Carol H Sampson; Hui Lin Chua; Mandar Joshi; Catherine Booth; Alec Gough; Cynthia S Johnson; Barry P Katz; Ann M Farese; Jeffrey Parker; Thomas J MacVittie; Christie M Orschell
Journal:  Health Phys       Date:  2012-10       Impact factor: 1.316

7.  Combined immunomodulator and antimicrobial therapy eliminates polymicrobial sepsis and modulates cytokine production in combined injured mice.

Authors:  Thomas B Elliott; David L Bolduc; G David Ledney; Juliann G Kiang; Oluseyi O Fatanmi; Stephen Y Wise; Patricia L P Romaine; Victoria L Newman; Vijay K Singh
Journal:  Int J Radiat Biol       Date:  2015-06-08       Impact factor: 2.694

8.  Ciprofloxacin modulates cytokine/chemokine profile in serum, improves bone marrow repopulation, and limits apoptosis and autophagy in ileum after whole body ionizing irradiation combined with skin-wound trauma.

Authors:  Risaku Fukumoto; Lynnette H Cary; Nikolai V Gorbunov; Eric D Lombardini; Thomas B Elliott; Juliann G Kiang
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

9.  Management of Radiation Injuries by Panax ginseng Extract.

Authors:  Preeti Verma; Swafiya Jahan; Tae Hawn Kim; Pradeep Kumar Goyal
Journal:  J Ginseng Res       Date:  2011-09       Impact factor: 6.060

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.